Anti-IFNα immunization raises the IFNα-neutralizing capacity of serum - An adjuvant to antiretroviral tritherapy

Biomedicine and Pharmacotherapy

Volumn 53, Issue 2, 1999, Pages 90-92

  Zagury, D ^a   Lecoq, H ^a   Gervi, I ^e   Le Buanec, H ^a   Zagury, J F ^a   Bizzini, B ^a   Burny, A ^b   Hermans, P ^c   Perja, M ^d   Santagostino, E ^d   Gringeri, A ^d  

^a SORBONNE UNIVERSITÉ   (France)

^b FREE UNIVERSITY OF BRUSSELS   (Belgium)

^c SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^d UNIVERSITY OF MILAN   (Italy)

^e NONE

Author keywords

Anti IFN vaccine; HAART; IFN neutralizing capacity

Indexed keywords

ALPHA2B INTERFERON; ANTIRETROVIRUS AGENT; INTERFERON ANTIBODY; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIRUS NEUTRALIZATION;

EID: 0033102085     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(99)80065-1     Document Type: Article

References (8)

1. 1 Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278 : 1295-300.
2. + T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 1998; 95 : 8869-73.
3. 3 Zagury JF, Chams V, Lachgar A. Carcagno M, Rappaport J, Bizzini B, et al. Model of AIDS immunopathogenesis based on the HIV-1 gp120 and Tat-induced dysregulation of uninfected immune cells. AIDS Sci 1996; 3 : 123-8.
4. 4 Zagury D, Lachgar A, Chams V, Fall LS, Bernard J, Zagury JF, et al. Interferon α and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. Proc Natl Acad Sci USA 1998; 95 : 3851-6.
5. 5 Gringeri A, Santagostino E. Muça-Perja M, Le Buanec H, Bizzini B, Lachgar A, et al. Tat-Toxoid, a sate and immunogenic component tor a preventive vaccine in seronegative subjects. JAIDS 1999 (in press).
6. 6 Fall LS, Chams V, Le Coq H, Fouchard M, M'Bika JP, Gringeri A, et al. Evidence for an antiviral effect and interferon neutralizing capacity in human sera; variability and implications for HIV infection. Cell Mol Biol 1995; 41 : 409-16.
7. 7 Gringeri A, Santagostino E, Mannucci PM, Tradati F, Cultraro D, Buzzi D, et al. A randomized, placebo-controlled, blind anti-AIDS clinical trial: safety and immunogenicity of a specific anti-IFNα immunization. JAIDS 1994; 7 : 978-88.
8. 8 Gringeri A, Santagostino E, Cusini M. Muça-Perja M, Marioni A, Mannucci PM, et al. Absence of clinical, virological and immunological signs of progression in HIV-1 infected patients receiving active anti-alpha interferon immunization: a 30 month follow-up report. JAIDS 1996; 13 : 55-67.